- Home
- AUGO vs SUPN Comparison
AUGO vs SUPN Comparison
Compare AUGO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUGO
- SUPN
- Stock Information
- Founded
- AUGO 1946
- SUPN 2005
- Country
- AUGO United States
- SUPN United States
- Employees
- AUGO N/A
- SUPN N/A
- Industry
- AUGO
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- AUGO
- SUPN Health Care
- Exchange
- AUGO Nasdaq
- SUPN Nasdaq
- Market Cap
- AUGO 3.1B
- SUPN 2.6B
- IPO Year
- AUGO N/A
- SUPN 2012
- Fundamental
- Price
- AUGO $30.84
- SUPN $52.72
- Analyst Decision
- AUGO Strong Buy
- SUPN Strong Buy
- Analyst Count
- AUGO 2
- SUPN 3
- Target Price
- AUGO $45.80
- SUPN $62.67
- AVG Volume (30 Days)
- AUGO 544.4K
- SUPN 725.2K
- Earning Date
- AUGO 11-04-2025
- SUPN 11-04-2025
- Dividend Yield
- AUGO 4.79%
- SUPN N/A
- EPS Growth
- AUGO N/A
- SUPN 1411.53
- EPS
- AUGO N/A
- SUPN 1.14
- Revenue
- AUGO $679,914,000.00
- SUPN $665,125,000.00
- Revenue This Year
- AUGO $46.44
- SUPN $7.31
- Revenue Next Year
- AUGO $39.06
- SUPN $21.87
- P/E Ratio
- AUGO N/A
- SUPN $46.18
- Revenue Growth
- AUGO 35.59
- SUPN 5.55
- 52 Week Low
- AUGO $22.24
- SUPN $29.16
- 52 Week High
- AUGO $41.04
- SUPN $53.28
- Technical
- Relative Strength Index (RSI)
- AUGO N/A
- SUPN 78.22
- Support Level
- AUGO N/A
- SUPN $49.95
- Resistance Level
- AUGO N/A
- SUPN $52.15
- Average True Range (ATR)
- AUGO 0.00
- SUPN 1.36
- MACD
- AUGO 0.00
- SUPN 0.30
- Stochastic Oscillator
- AUGO 0.00
- SUPN 97.61
About AUGO Aura Minerals Inc. Common Shares
Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments are its operating assets and include The Minosa Mine, the Apoena Mine, the Aranzazu Mine, the Almas Mine; and projects (Matupa, Tolda Fria, Borborema and Carajas Projects, and Corporate).
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.